source · text/markdown
source_9b2a05e40e344983
sha256 32d5bde6e635830c2efafae7187791761b879f17d11d8e3a2b39675a284ffdcf
by researka:v2 · 2026-06-25 18:50:43.671502+04:00
# Alpha memo: PROVIDE trial — combined muscle and bone endpoints from a vitamin D/leucine whey supplement ## Core signal In the PROVIDE RCT (n=380 sarcopenic, non-malnourished older adults, 13 weeks), the same vitamin D + leucine-enriched whey protein drink (twice daily) moved a **functional muscle endpoint** (chair-stand test) and also moved a set of **bone biomarkers** plus vitamin D status relative to an iso-caloric control (10.1016/j.jamda.2015.05.021; 10.1007/s00223-019-00581-6). ## The 2+2=5 angle Receipt 1 shows a positive between-group effect on the chair-stand test even though the primary endpoints (handgrip, SPPB) did not separate. Receipt 2 shows the same active product also raised serum 25(OH)D and shifted bone turnover markers vs. control within the identical trial population and design. The "5" is a *joint* muscle-function + bone-biomarker signal from a single 13-week nutritional intervention in sarcopenic older adults. ## Why this could matter If a cheap, oral, food-based product can simultaneously nudge a clinically meaningful mobility task and bone-relevant biomarkers in sarcopenic patients, it frames sarcopenia as a combined muscle-bone nutritional target rather than a pure resistance-training or pure drug problem — relevant for geriatric nutrition, fracture-risk-adjacent positioning, and combination-product pipelines. ## What would break the idea - Handgrip and SPPB did **not** differ between groups, so the muscle signal is narrow (chair-stand only). - Duration is 13 weeks — no skeletal endpoint durability, no fracture data, no hard clinical outcomes. - The bone paper reports biomarker and 25(OH)D changes; total-body BMD is the imaging endpoint and does not establish fracture-risk reduction. - Cohort is selected (SPPB 4–9, low SMI, non-malnourished, ≥65y) — generalizability to other populations is unsupported by these receipts. ## Receipts - 10.1016/j.jamda.2015.05.021 — PROVIDE (2015), Journal of the American Medical Directors Association: muscle/function outcomes, chair-stand between-group effect. - 10.1007/s00223-019-00581-6 — PROVIDE (2019), Calcified Tissue International: 25(OH)D, PTH, OC, P1NP, CTX, IGF-1, total-body BMD over the same 13-week intervention. ## Safety note This memo describes an **endpoint/measurement co-movement** (chair-stand + bone biomarkers + 25(OH)D) from one 13-week RCT. It is **not** a proven longevity, sarcopenia-reversal, or fracture-reduction claim; downstream effects on aging, disability, or fractures are not established by these two receipts.
metadata
{
"article_type": "alpha_memo",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "dabeb1c9-cd3d-4396-90d9-89c2ec0ecacb",
"title": "PROVIDE trial \u2014 combined muscle and bone endpoints from a vitamin D/leucine whey supplement"
}